Standing Order
Madrigal Pharmaceuticals, Inc.

Dashboard

Madrigal Pharmaceuticals, Inc.

MDGLNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$8.8B
Price$379.1052w $272.67 – $602.83
Conviction4/ 5
Revenue (TTM)$1.4B
Revenue growth YoY+92.8%
P/E (trailing)—
Gross margin91.0%
Operating margin-10.7%
Net margin-10.9%
52w price change+39.0%
Next earnings—

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Nov 16
    Trial initiationClinicalTrials.gov

    Phase 4 trial (NCT07848191) recruiting for Rezdiffra with concomitant therapies in adults with MASH and F2-F3 fibrosis.

  • Nov 12
    Trial initiationClinicalTrials.gov

    Phase 1 trial NCT07830758 of resmetirom in MASH and HFpEF updated to recruiting status.

  • Nov 6
    Ownership changeSEC

    Form 4 insider transaction filing on 2026-11-06.

  • Nov 6
    Ownership changeSEC

    Form 4 insider transaction filing reported.

  • Nov 3
    Financial resultsSEC

    Madrigal Pharmaceuticals filed 8-K (items 2.02, 9.01) disclosing results of operations and financial condition.

  • Oct 16
    Trial initiationClinicalTrials.gov

    Phase 1 trial of resmetirom in MASH and HFpEF initiated and recruiting (NCT07830758)

  • Oct 16
    Trial initiationClinicalTrials.gov

    Phase 4 trial (NCT07848191) of Rezdiffra with concomitant therapies in MASH patients with F2-F3 fibrosis now recruiting.

  • Sep 29
    Trial initiationClinicalTrials.gov

    Madrigal plans Phase 4 trial of Rezdiffra with concomitant therapies in MASH patients with F2-F3 fibrosis (NCT07848191, not yet recruiting)

  • Sep 21
    Trial initiationClinicalTrials.gov

    Phase 1 trial initiation of resmetirom in MASH patients with HFpEF (NCT07830758, not yet recruiting)

  • Sep 11
    Ownership changeSEC

    Form 4 insider transaction filing dated 2026-09-11.

  • Sep 11
    Trial initiationClinicalTrials.gov

    Madrigal initiates Phase 2 trial of resmetirom in children and adolescents with MASH (NCT07763015, recruiting).

  • Aug 26
    Trial initiationClinicalTrials.gov

    Madrigal initiates Phase 2 trial of resmetirom in post-liver transplant MASH patients (NCT07335601, recruiting).

  • Aug 20
    Ownership changeSEC

    Form 4 filing for insider transaction at Madrigal Pharmaceuticals.

  • Aug 18
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Aug 13
    Trial initiationClinicalTrials.gov

    Madrigal initiates Phase 2 trial of resmetirom in children and adolescents with MASH (NCT07763015), status not yet recruiting.

  • Aug 12
    LeadershipSEC

    8-K filed with items 5.02, 7.01, 9.01 covering officer/director changes and related disclosures.

  • Jul 31
    Trial initiationClinicalTrials.gov

    Madrigal initiates Phase 2 trial (NCT07335601) of resmetirom in post-liver transplant MASH patients; status recruiting.

  • Jul 30
    Financial resultsSEC

    8-K filing (items 2.02, 9.01) reporting results of operations and financial condition.

  • Jul 20
    Ownership changeSEC

    Form 4 insider transaction filing

  • Jul 8
    OtherClinicalTrials.gov

    Phase 3 MAESTRO-NASH-OUTCOMES trial (NCT05500222) for resmetirom in NASH cirrhosis status updated to ACTIVE_NOT_RECRUITING.

Not financial advice — research and opinion only. Disclosures